We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory squamous cell carcinoma of the head and neck (SCCHN).Patients with R/M SCCHN with tumor progression/recurrence within 6?months of platinum therapy were randomized 2:1 to nivolumab 3?mg/kg every 2?weeks or investigator's choice (IC). Primary endpoint: overall survival (OS). Data cutoff: September 2017.With 24.2?months' minimum follow-up, nivolumab (n?=?240) continued to improve OS vs IC (n?=?121), hazard ratio (HR)?=?0.68 (95% CI 0.54-0.86). Nivolumab nearly tripled the estimated 24-month OS rate (16.9%) vs IC (6.0%), and demonstrated OS benefit across patients with tumor PD-L1 expression =1% (HR [95% CI]?=?0.55 [0.39-0.78]) and ?
View details for PubMedID 29884413